Business Context and Reporting Period
Company: Scinai Immunotherapeutics Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: First half of 2026 (as of June 30, 2026)
Filing Date: August 24, 2026
This filing serves as a conduit for a business update, condensed interim unaudited financial statements, and an operating and financial review. The primary content is contained within attached Exhibits 99.1, 99.2, and 99.3.
Key Financial Metrics
The provided text is a cover sheet and does not contain specific numerical data for revenue, profit, cash flow, margins, debt, or liquidity. These figures are located in the attached Exhibit 99.2 (Condensed Consolidated Unaudited Financial Statements) and Exhibit 99.3 (Operating and Financial Review), which are not included in the input text.
Material Changes
The filing text does not provide specific details regarding material changes versus the prior comparable period. Such analysis is expected to be found in the attached business update (Exhibit 99.1) and financial review (Exhibit 99.3).
Guidance, Outlook, and Risks
Management commentary, outlook, risks, contingencies, and unusual items are referenced as being included in the attached exhibits but are not detailed in the cover document. The filing incorporates these exhibits by reference into the company's Registration Statements on Form S-8 and Form F-3.
Investor Verification Checklist
- Review Exhibit 99.1 for the specific business update and operational milestones for the first half of 2026.
- Analyze Exhibit 99.2 for the condensed interim unaudited financial statements to verify cash position and burn rate.
- Examine Exhibit 99.3 for the management discussion regarding operating prospects and financial review.
- Confirm the incorporation of this report into active Registration Statements (File Nos. 333-291460, 333-271293, 333-239344, 333-295698, 333-274078, and 333-276767).